四环生物(000518) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was ¥78,228,965.06, a decrease of 9.52% compared to the same period last year[5] - Net profit attributable to shareholders was -¥2,428,434.71, a decline of 149.68% year-on-year[5] - Total operating revenue for Q3 2022 was ¥196.63 million, a decrease of 16.76% from ¥236.21 million in the same period last year[15] - Total profit for the period was -¥38,968,155.80, a decline of 58.86% year-on-year attributed to decreased revenue[8] - Net loss for Q3 2022 was ¥38.63 million, compared to a net loss of ¥25.78 million in Q3 2021, representing a 49.73% increase in losses[16] - The company's gross profit margin decreased to -16.69% in Q3 2022 from -4.67% in Q3 2021[15] Cash Flow - Cash flow from operating activities showed a net increase of ¥10,971,676.12, representing a 189.91% increase compared to the previous year[5] - The net cash flow from operating activities for the period was ¥10,971,676.12, compared to a negative cash flow of ¥12,202,601.96 in the previous period, indicating a significant improvement[17] - Total cash inflow from operating activities was ¥216,954,395.65, down 18.2% from ¥265,224,529.22 in the same period last year[17] - Cash outflow from operating activities totaled ¥205,982,719.53, a decrease of 25.8% from ¥277,427,131.18 in the previous year[17] - The cash flow from investment activities was negative at ¥16,380,130.00, compared to a negative cash flow of ¥3,732,208.77 in the same period last year[18] - The net cash flow from financing activities was negative at ¥1,628,250.30, compared to a negative cash flow of ¥516,200.02 in the previous year[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥757,659,060.87, down 5.21% from the end of the previous year[5] - As of September 30, 2022, total current assets amounted to CNY 578,099,705.50, a decrease of 6.8% from CNY 620,440,744.86 at the beginning of the year[11] - The total liabilities as of Q3 2022 amounted to ¥149.51 million, a slight decrease from ¥152.54 million at the end of the previous period[15] - The total equity attributable to shareholders of the parent company was ¥570.68 million, down from ¥606.03 million in the previous period[15] Shareholder Information - The top shareholder, Yu Qinfeng, holds 14.32% of the shares, with a total of 147,381,643 shares, of which 139,860,000 are pledged[10] - The second-largest shareholder, Wang Hongming, owns 14.00% of the shares, totaling 144,138,394 shares, with 144,130,000 pledged[10] - The company has a total of 108,400 common shareholders as of the end of the reporting period[10] Operational Metrics - The company reported a significant increase in accounts receivable financing by 123.85% to ¥6,663,552.76[8] - Long-term equity investments decreased by 54.43% to ¥335,349.37 due to increased losses from joint ventures[8] - Other income from government subsidies decreased by 93.94% to ¥174,351.88 compared to the previous year[8] - The company reported a significant increase in accounts payable, rising to ¥63.81 million from ¥60.77 million year-on-year[15] - Research and development expenses for Q3 2022 were ¥46.09 million, a decrease of 22.00% from ¥59.10 million in the previous year[15] Development and Future Plans - The company plans to continue investing in new production projects, particularly in Beijing, which has already seen an increase in development expenditures by 70.08% to ¥30,580,000.00[8] - The company reported a significant increase in development expenditures, rising to CNY 30,580,000.00 from CNY 17,980,000.00, an increase of 70.5%[12] Miscellaneous - The report was not audited, indicating that the figures may be subject to change upon final review[19] - The company's cash and cash equivalents showed a net decrease of ¥6,760,627.38, an improvement of 58.86% compared to the previous year[8] - Cash and cash equivalents decreased to CNY 31,601,405.64 from CNY 38,111,291.58, reflecting a decline of 17.5%[12] - Accounts receivable decreased to CNY 96,736,079.01 from CNY 119,306,867.86, a reduction of 18.9%[12] - Inventory stood at CNY 425,846,450.46, slightly down from CNY 430,665,018.49, indicating a decrease of 1.1%[12] - Total non-current assets increased to CNY 179,559,355.37 from CNY 178,871,329.26, showing a growth of 0.4%[12]